| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $452K | +51.7% | +16.8% |
| R&D Expense | $13.8M | -7.2% | +21.1% |
| SG&A Expense | $7.7M | +6.6% | +17.6% |
| Operating Income | -$21.1M | +3.4% | -19.9% |
| Net Income | -$35.9M | -326.0% | -48.5% |
| EPS (Basic) | -$1.38 | -370.6% | -22.1% |
| EPS (Diluted) | -$1.38 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $143.4M | -10.6% | -34.6% |
| Accounts Receivable | $722K | +104.0% | -85.0% |
| Current Assets | $147.3M | -9.9% | -35.7% |
| Total Assets | $372.7M | -4.2% | -18.2% |
| Current Liabilities | $13.8M | +12.6% | -35.5% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$56.2M | — | — |
| Capital Expenditures | $5.0M | — | — |
| Investing Cash Flow | -$5.0M | — | — |
| Financing Cash Flow | -$8.0M | — | — |
| Free Cash Flow | -$61.2M | — | — |
| -376.0% |
| -22.1% |
| $408.5M |
| +4.4% |
| -10.1% |
| Stockholders' Equity | -$35.8M | -1318.4% | -4866.5% |